Compare EPM & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EPM | CDXS |
|---|---|---|
| Founded | 2003 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Major Chemicals |
| Sector | Energy | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.2M | 141.8M |
| IPO Year | 1996 | 2010 |
| Metric | EPM | CDXS |
|---|---|---|
| Price | $3.66 | $1.78 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $4.93 | N/A |
| AVG Volume (30 Days) | 593.4K | ★ 986.3K |
| Earning Date | 02-10-2026 | 02-26-2026 |
| Dividend Yield | ★ 13.52% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $85,232,000.00 | $52,932,000.00 |
| Revenue This Year | N/A | $15.64 |
| Revenue Next Year | $1.22 | $5.23 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.19 | $1.52 |
| 52 Week High | $5.70 | $5.43 |
| Indicator | EPM | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 50.66 | 56.19 |
| Support Level | $3.19 | $1.61 |
| Resistance Level | $3.42 | $1.74 |
| Average True Range (ATR) | 0.13 | 0.07 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 87.74 | 100.00 |
Evolution Petroleum Corp is an independent energy company focused on owning and investing in onshore oil and natural gas properties across the United States. Its portfolio includes non-operated interests in various production fields such as CO2 enhanced oil recovery in Louisiana, secondary recovery production in Wyoming, and shale gas reservoirs in Texas and North Dakota. The company generates revenue from the production and sale of oil and natural gas, leveraging specialized technologies to extend reservoir life and enhance recoveries.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.